These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38788824)

  • 81. Preventing gastrointestinal complications of NSAIDs. Risk factors, recent advances, and latest strategies.
    Graumlich JF
    Postgrad Med; 2001 May; 109(5):117-20, 123-8. PubMed ID: 11381661
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs.
    García Rodríguez LA
    Am J Med; 1998 Mar; 104(3A):30S-34S; discussion 41S-42S. PubMed ID: 9572318
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Impact of COX-2 inhibitors in common clinical practice a gastroenterologist's perspective.
    Lehmann FS; Beglinger C
    Curr Top Med Chem; 2005; 5(5):449-64. PubMed ID: 15974940
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [Further definition of the role of COX-2 inhibitors and NSAIDs in patients with nociceptive pain].
    Nurmohamed MT
    Ned Tijdschr Geneeskd; 2007 Jun; 151(23):1313; author reply 1313-4. PubMed ID: 17624165
    [No Abstract]   [Full Text] [Related]  

  • 85. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs.
    Warner TD; Mitchell JA
    Lancet; 2008 Jan; 371(9608):270-3. PubMed ID: 18207021
    [No Abstract]   [Full Text] [Related]  

  • 86. [Epidemiology study on upper gastrointestinal lesions induced by non-steroidal anti-inflammatory drugs].
    Shiokawa Y; Nobunaga M; Saito T; Asaki S; Ogawa N
    Ryumachi; 1991 Feb; 31(1):96-111. PubMed ID: 1858000
    [No Abstract]   [Full Text] [Related]  

  • 87. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.
    Brown TJ; Hooper L; Elliott RA; Payne K; Webb R; Roberts C; Rostom A; Symmons D
    Health Technol Assess; 2006 Oct; 10(38):iii-iv, xi-xiii, 1-183. PubMed ID: 17018227
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations.
    Lazzaroni M; Bianchi Porro G
    Aliment Pharmacol Ther; 2004 Jul; 20 Suppl 2():48-58. PubMed ID: 15335413
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Nonsteroidal anti-inflammatory agents and gastrointestinal pathology].
    Lanas AI
    Gastroenterol Hepatol; 1995 Mar; 18(3):142-52. PubMed ID: 7621292
    [No Abstract]   [Full Text] [Related]  

  • 90. NSAID gastroenteropathy: past, present and future.
    Wallace JL
    Can J Gastroenterol; 1996; 10(7):451-9. PubMed ID: 9113889
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [Gastrointestinal side effects of non-steroidal anti-inflammatory agents and costs in the National Health System].
    Lanas A
    An Med Interna; 2001 Nov; 18(11):561-3. PubMed ID: 11862764
    [No Abstract]   [Full Text] [Related]  

  • 92. [Nonsteroidal-anti-inflammatory drugs and serious undesirable gastrointestinal effects].
    Fabijanić D; Kardum D; Banić M; Fabijanić A
    Lijec Vjesn; 2007; 129(6-7):205-13. PubMed ID: 18018712
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Non-steroidal anti-inflammatory drugs (NSAIDs).
    Day RO; Graham GG
    BMJ; 2013 Jun; 346():f3195. PubMed ID: 23757736
    [No Abstract]   [Full Text] [Related]  

  • 94. Gastrointestinal risk of non-steroidal anti-inflammatory drugs and gastroprotective agents used in the treatment of osteoarthritis in elderly patients: A nationwide retrospective cohort study
.
    Han MH; Nam JH; Noh E; Lee EK
    Int J Clin Pharmacol Ther; 2019 Nov; 57(11):531-541. PubMed ID: 31397273
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Knowledge and perceptions of the risks of non-steroidal anti-inflammatory drugs among orthopaedic patients in Thailand.
    Phueanpinit P; Pongwecharak J; Krska J; Jarernsiripornkul N
    Int J Clin Pharm; 2016 Oct; 38(5):1269-76. PubMed ID: 27473713
    [TBL] [Abstract][Full Text] [Related]  

  • 96. [Nonsteroidal antiinflammatory drugs: gastrointestinal and cardiovascular and renal safety].
    Oscanoa-Espinoza T; Lizaraso-Soto F
    Rev Gastroenterol Peru; 2015 Jan; 35(1):63-71. PubMed ID: 25875519
    [TBL] [Abstract][Full Text] [Related]  

  • 97. [Renal risks of NSAIDs in endurance sports].
    Chabbey E; Martin PY
    Rev Med Suisse; 2019 Feb; 15(639):444-447. PubMed ID: 30785678
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The development of gastrointestinal-sparing nonsteroidal anti-inflammatory drugs.
    Wallace JL; Cirino G
    Trends Pharmacol Sci; 1994 Nov; 15(11):405-6. PubMed ID: 7855901
    [No Abstract]   [Full Text] [Related]  

  • 99. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Induced Dyspepsia.
    Yap PR; Goh KL
    Curr Pharm Des; 2015; 21(35):5073-81. PubMed ID: 26369685
    [TBL] [Abstract][Full Text] [Related]  

  • 100. [Can COX-2 selective inhibitor prevent NSAIDs-related GI toxicity?].
    Konishi H; Yoshikawa T
    Nihon Rinsho; 2011 Jun; 69(6):1110-5. PubMed ID: 21688637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.